Open Access
Volume 23, Numéro 1, January-February 2016
Numéro d'article D109
Nombre de pages 7
Section Dossier: Lipids and Brain / Lipides et cerveau
Publié en ligne 2 octobre 2015
  • Bazan NG. 2003. Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor. J. Lipid Res. 44: 2221–2233. [CrossRef] [Google Scholar]
  • Bazan NG. 2005. Neuroprotectin D1 (NPD1): A DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 15: 159–166. [CrossRef] [PubMed] [Google Scholar]
  • Bazan NG. 2006. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci. 29: 263–271. [CrossRef] [Google Scholar]
  • Bazan NG. 2007. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr. Opin. Clin. Nutr. Metab. Care 10: 136–141. [Google Scholar]
  • Bazan NG, Gordon WC, Rodriguez de Turco EB. 1992. Docosahexaenoic acid uptake and metabolism in photoreceptors: retinal conservation by an efficient retinal pigment epithelial cell-mediated recycling process. Adv. Exp. Med. Biol. 318: 295–306. [CrossRef] [PubMed] [Google Scholar]
  • Bazan NG, Molina MF, Gordon WC. 2011. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Annu. Rev. Nutr. 31: 321–351. [CrossRef] [PubMed] [Google Scholar]
  • Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. 1997. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J. Neurosurg. 87: 595–601. [Google Scholar]
  • Belayev L, Zhao W, Pattany PM, et al. 1998. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke 12: 2587–2599. [Google Scholar]
  • Belayev L, Alonso OF, Huh PW, et al. 1999. Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats. J. Neurotrauma 6: 445-453. [Google Scholar]
  • Belayev L, Pinard E, Nallet H, et al. 2002. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 4: 1077–1084. [Google Scholar]
  • Belayev L, Marcheselli VL, Khoutorova L, et al. 2005. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 36: 118–123. [CrossRef] [PubMed] [Google Scholar]
  • Belayev L, Khoutorova L, Atkins KD, et al. 2009. Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke 40: 3121–3126. [CrossRef] [PubMed] [Google Scholar]
  • Belayev L, Khoutorova L, Atkins KD, et al. 2011. Docosahexaenoic acid therapy of experimental ischemic stroke. Transl. Stroke Res. 2: 33–41. [CrossRef] [PubMed] [Google Scholar]
  • Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. 2001. Human albumin therapy of acute ischemic stroke marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 32: 553–560. [CrossRef] [PubMed] [Google Scholar]
  • Chen RL, Balami JS, Esiri MM, Chen LK, Buchan AM. 2010. Ischemic stroke in the elderly: an overview of evidence. Nat. Rev. Neurol. 6: 256–265. [CrossRef] [PubMed] [Google Scholar]
  • Eady TN, Khoutorova L, Atkins KD, Bazan NG, Belayev L. 2012. Docosahexaenoic acid complexed to human albumin in experimental stroke: neuroprotective efficacy with a wide therapeutic window. Exp. Transl. Stroke Med. 4: 19. [Google Scholar]
  • Eady TN, Khoutorova L, Anzola DV, et al. 2013. Acute treatment with docosahexaenoic acid complexed to albumin reduces injury after a permanent focal cerebral ischemia in rats. PLoS One 8: e77237. [CrossRef] [PubMed] [Google Scholar]
  • Feigin VL, Lawes CM, Bennett DA, Anderson CS. 2003. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2: 43–53. [CrossRef] [PubMed] [Google Scholar]
  • Fisher M, Bastan B. 2008. Treating acute ischemic stroke. Curr. Opin. Drug. Discov. Devel. 11: 626–632. [PubMed] [Google Scholar]
  • Ginsberg MD, Palesch YY, Martin RH, et al. 2011. The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke 42: 119–127. [CrossRef] [PubMed] [Google Scholar]
  • Herson PS, Traystman RJ. 2014. Animal models of stroke: translational potential at present and in 2050. Future Neurol. 9: 541–551. [CrossRef] [PubMed] [Google Scholar]
  • Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. 2004. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. J. Am. Med. Assoc. 292: 1831–1838. [CrossRef] [PubMed] [Google Scholar]
  • Huh PW, Belayev L, et al. 1998. The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res. 1: 105–113. [Google Scholar]
  • Kassem-Moussa H, Graffagnino C. 2002. Nonocclusion and spontaneous recanalization rates in acute ischemic stroke: a review of cerebral angiography studies. Arch. Neurol. 59: 1870–1873. [CrossRef] [PubMed] [Google Scholar]
  • Liu F, McCullough LD. 2011. Middle cerebral artery occlusion model in rodents: methods and potential pitfalls. J. Biomed. Biotechnol. 2011: 464701. [PubMed] [Google Scholar]
  • Liu F, Yuan R, Benashski SE, McCullough LD. 2009. Changes in experimental stroke outcome across the life span. J. Cereb. Blood Flow Metab. 29: 792–802. [Google Scholar]
  • Marcheselli VL, Hong S, Lukiw WJ, et al. 2003. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278: 43807–43817. [CrossRef] [Google Scholar]
  • Mozaffarian D, Benjamin EJ, Go AS, et al. 2015. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation 131: e29–322. [CrossRef] [PubMed] [Google Scholar]
  • Muralikrishna Adibhatla R, Hatcher JF. 2006. Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic. Biol. Med. 40: 376–387. [CrossRef] [Google Scholar]
  • O’Collins VE, Macleod MR, Donnan GA, et al. 2006. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59: 467–477. [Google Scholar]
  • Rapoport SI, Chang MC, Spector AA. 2001. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J. Lipid Res. 42: 678–685. [Google Scholar]
  • Rodriguez de Turco EB, Belayev L, Liu Y, et al. 2002. Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J. Neurochem. 83: 515–524. [CrossRef] [PubMed] [Google Scholar]
  • Sheng H, Yang W, Fukuda S, et al. 2009. Long-term neuroprotection from a potent redox-modulating metalloporphyrin in the rat. Free Radic. Biol. Med. 47: 917–923. [CrossRef] [Google Scholar]
  • Simopoulos AP. 2008. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med. (Maywood) 6: 674–688. [Google Scholar]
  • Stroke Therapy Academic Industry Roundtable. 1999. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30: 2752–2758. [Google Scholar]
  • Turner RC, Lucke-Wold B, Lucke-Wold N, et al. 2013. Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions. Int. J. Mol. Sci. 14: 1890–1917. [CrossRef] [PubMed] [Google Scholar]
  • Tymianski M. 2013. Novel approaches to neuroprotection trials in acute ischemic stroke. Stroke 44: 2942–2950. [CrossRef] [PubMed] [Google Scholar]
  • Valtysson J, Hillered L, Andine P, Hagberg H, Persson L. 1994. Neuropathological endpoints in experimental stroke pharmacotherapy: the importance of both early and late evaluation. Acta Neurochir. (Wien) 129: 58–63. [Google Scholar]
  • Wagner JC, Lutsep HL. 2005. Thrombolysis in young adults. J. Thromb. Thrombolysis 20: 133–136. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.